Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medroxyprogesterone vs Venlafaxine for Hot Flashes
NCT00030914Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2002
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venlafaxine in hot flashes (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Hot Flash Frequency Reduction at 6 weeks and Hot Flash Score Reduction at 6 weeks. Started Apr 2002; status: completed.
02
Drugs
venlafaxine
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT00030914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030914.